A Multicenter Randomized Phase III Trial Comparing MET Tyrosine Kinase Inhibitors vs. Immune Checkpoint Inhibitors With or Without Chemotherapy as First-Line Treatment for Patients With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutations: JCOG2506 (DECIDE-MET).

Tabrecta (capmatinib) - Novartis

Tepmetko (tepotinib) - EMD Serono

Keytruda (pembrolizumab) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/42753422

; Haruhiko Fukuda; Hirotsugu Kenmotsu; Isamu Okamoto; Kei Kunimasa; Ken Masuda; Kota Kawabata; Masahiko Ando; Noriko Mitome; Shogo Nomura; Yasushi Goto; Yoshimasa Shiraishi

Sep 18, 2026